JPMorgan Reiterates Overweight Rating on Vera Therapeutics (VERA), Top Idea
Tweet Send to a Friend
JPMorgan analyst Anupam Rama reiterated an Overweight rating and $68.00 price target on Vera Therapeutics (NASDAQ: VERA).The analyst comments "This ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


